NOMAD POWER SOLUTIONS, INC. (NMAD) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
15/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinNMAD / S&P 141.69% / 15.20% |
LoseNMAD / S&P NMAD unavailable / 15.00% |
LoseNMAD / S&P -21.71% / 50.40% |
| 2026-Q10/3 |
LoseNMAD / S&P -21.88% / -4.33% |
LoseNMAD / S&P NMAD unavailable / 11.30% |
LoseNMAD / S&P -21.38% / 27.70% |
| 2025-Q40/3 |
LoseNMAD / S&P -21.87% / 2.65% |
LoseNMAD / S&P NMAD unavailable / 9.00% |
LoseNMAD / S&P -21.38% / 13.40% |
| 2025-Q31/3 |
WinNMAD / S&P 452.75% / 8.12% |
LoseNMAD / S&P NMAD unavailable / 4.61% |
LoseNMAD / S&P -31.79% / 13.45% |
| 2025-Q20/3 |
LoseNMAD / S&P -24.79% / 10.94% |
LoseNMAD / S&P NMAD unavailable / 4.83% |
LoseNMAD / S&P -27.53% / 10.63% |
| 2025-Q10/3 |
LoseNMAD / S&P -40.39% / -4.27% |
LoseNMAD / S&P NMAD unavailable / 4.98% |
LoseNMAD / S&P -37.77% / 10.57% |
| 2024-Q41/3 |
WinNMAD / S&P 8.56% / 2.41% |
LoseNMAD / S&P NMAD unavailable / 5.25% |
LoseNMAD / S&P -41.54% / 6.15% |
| 2024-Q30/3 |
LoseNMAD / S&P -21.10% / 5.89% |
LoseNMAD / S&P NMAD unavailable / 5.89% |
LoseNMAD / S&P -47.42% / 6.11% |
| 2024-Q20/3 |
LoseNMAD / S&P -29.88% / 4.28% |
LoseNMAD / S&P NMAD unavailable / 5.38% |
LoseNMAD / S&P -51.76% / 5.12% |
| 2024-Q11/3 |
WinNMAD / S&P 43.83% / 10.56% |
LoseNMAD / S&P NMAD unavailable / 5.71% |
LoseNMAD / S&P -35.99% / 5.59% |
| 2023-Q40/3 |
LoseNMAD / S&P -4.08% / 11.69% |
LoseNMAD / S&P NMAD unavailable / 6.81% |
LoseNMAD / S&P NMAD unavailable / 7.78% |
| 2023-Q30/3 |
LoseNMAD / S&P -58.33% / -3.27% |
LoseNMAD / S&P NMAD unavailable / 7.52% |
LoseNMAD / S&P NMAD unavailable / -5.03% |
| 2023-Q20/3 |
LoseNMAD / S&P -29.16% / 8.74% |
LoseNMAD / S&P NMAD unavailable / 9.50% |
LoseNMAD / S&P NMAD unavailable / -8.57% |
| 2023-Q11/3 |
WinNMAD / S&P 62.75% / 7.50% |
LoseNMAD / S&P NMAD unavailable / 10.77% |
LoseNMAD / S&P NMAD unavailable / -15.69% |
| 2022-Q40/3 |
LoseNMAD / S&P -8.93% / 7.56% |
LoseNMAD / S&P NMAD unavailable / 11.88% |
LoseNMAD / S&P NMAD unavailable / -17.99% |
| 2022-Q30/3 |
LoseNMAD / S&P -24.32% / -4.88% |
LoseNMAD / S&P NMAD unavailable / 13.47% |
LoseNMAD / S&P NMAD unavailable / -1.41% |
| 2022-Q20/3 |
LoseNMAD / S&P -39.84% / -16.10% |
LoseNMAD / S&P NMAD unavailable / 13.71% |
LoseNMAD / S&P NMAD unavailable / 11.04% |
| 2022-Q11/3 |
WinNMAD / S&P 3.36% / -4.60% |
LoseNMAD / S&P NMAD unavailable / 15.97% |
LoseNMAD / S&P NMAD unavailable / 42.23% |
| 2021-Q40/3 |
LoseNMAD / S&P -42.79% / 11.03% |
LoseNMAD / S&P NMAD unavailable / 15.00% |
LoseNMAD / S&P NMAD unavailable / 96.40% |
| 2021-Q30/3 |
LoseNMAD / S&P -31.35% / 0.58% |
LoseNMAD / S&P NMAD unavailable / 10.77% |
LoseNMAD / S&P NMAD unavailable / 69.42% |
| 2021-Q20/3 |
LoseNMAD / S&P -7.90% / 8.55% |
LoseNMAD / S&P NMAD unavailable / 6.58% |
LoseNMAD / S&P NMAD unavailable / 51.81% |
| 2021-Q10/3 |
LoseNMAD / S&P 3.79% / 6.17% |
LoseNMAD / S&P NMAD unavailable / -1.06% |
LoseNMAD / S&P NMAD unavailable / 7.39% |
| 2020-Q40/3 |
LoseNMAD / S&P -54.84% / 12.15% |
LoseNMAD / S&P NMAD unavailable / -3.72% |
LoseNMAD / S&P NMAD unavailable / -33.42% |
| 2020-Q31/3 |
WinNMAD / S&P 30.00% / 8.93% |
LoseNMAD / S&P NMAD unavailable / -2.04% |
LoseNMAD / S&P NMAD unavailable / -27.10% |
| 2020-Q20/3 |
LoseNMAD / S&P -8.16% / 20.54% |
LoseNMAD / S&P NMAD unavailable / -0.46% |
LoseNMAD / S&P NMAD unavailable / -27.11% |
| 2020-Q11/3 |
WinNMAD / S&P 44.12% / -19.60% |
LoseNMAD / S&P NMAD unavailable / 3.47% |
LoseNMAD / S&P NMAD unavailable / -14.75% |
| 2019-Q40/3 |
LoseNMAD / S&P -49.63% / 9.07% |
LoseNMAD / S&P NMAD unavailable / 5.36% |
LoseNMAD / S&P NMAD unavailable / 2.99% |
| 2019-Q31/3 |
WinNMAD / S&P 35.00% / 1.70% |
LoseNMAD / S&P NMAD unavailable / 5.02% |
LoseNMAD / S&P NMAD unavailable / 0.21% |
| 2019-Q21/3 |
WinNMAD / S&P 11.11% / 4.30% |
LoseNMAD / S&P NMAD unavailable / 6.64% |
LoseNMAD / S&P NMAD unavailable / 8.65% |
| 2019-Q10/3 |
LoseNMAD / S&P -3.23% / 13.65% |
LoseNMAD / S&P NMAD unavailable / 8.12% |
LoseNMAD / S&P NMAD unavailable / 14.29% |
| 2018-Q41/3 |
WinNMAD / S&P 24.00% / -13.52% |
LoseNMAD / S&P NMAD unavailable / 9.05% |
LoseNMAD / S&P NMAD unavailable / 18.23% |
| 2018-Q31/3 |
WinNMAD / S&P 167.86% / 7.71% |
LoseNMAD / S&P NMAD unavailable / 10.21% |
LoseNMAD / S&P NMAD unavailable / 19.06% |
| 2018-Q21/3 |
WinNMAD / S&P 115.38% / 3.43% |
LoseNMAD / S&P NMAD unavailable / 9.03% |
LoseNMAD / S&P NMAD unavailable / 14.46% |
| 2018-Q10/3 |
LoseNMAD / S&P -23.53% / -0.76% |
LoseNMAD / S&P NMAD unavailable / 7.68% |
LoseNMAD / S&P NMAD unavailable / 12.46% |
| 2017-Q41/3 |
WinNMAD / S&P 41.67% / 6.64% |
LoseNMAD / S&P NMAD unavailable / 7.03% |
LoseNMAD / S&P NMAD unavailable / 13.82% |
| 2017-Q30/3 |
LoseNMAD / S&P 0.00% / 4.48% |
LoseNMAD / S&P NMAD unavailable / 5.68% |
LoseNMAD / S&P NMAD unavailable / 17.57% |
| 2017-Q20/3 |
LoseNMAD / S&P -52.00% / 3.09% |
LoseNMAD / S&P NMAD unavailable / 4.83% |
LoseNMAD / S&P NMAD unavailable / 17.74% |
| 2017-Q11/3 |
WinNMAD / S&P 78.57% / 6.07% |
LoseNMAD / S&P NMAD unavailable / 3.67% |
LoseNMAD / S&P NMAD unavailable / 13.32% |
| 2016-Q40/3 |
LoseNMAD / S&P -30.00% / 3.82% |
LoseNMAD / S&P NMAD unavailable / 2.09% |
LoseNMAD / S&P NMAD unavailable / 7.05% |
| 2016-Q30/3 |
LoseNMAD / S&P 0.00% / 3.85% |
LoseNMAD / S&P NMAD unavailable / 0.20% |
LoseNMAD / S&P NMAD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NMAD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -0.67% | 20.78% |
| Annualized return | -0.67% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NMAD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -82.73% | 83.14% |
| Annualized return | -29.62% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | NMAD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -63.17% | 319.30% |
| Annualized return | -9.51% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |